Results 181 to 190 of about 24,946,579 (254)

Mitochondrial OXPHOS restricts SARS-CoV-2 replication. [PDF]

Sci Adv
Soto Albrecht YE, Morrow RM, Kenney D, Olali AZ, Wacquiez A, Chehadeh N, Cen Z, Haltom JA, Chen I, Ranshing SS, Widjaja GA, Angelin A, Tintos-Hernandez JA, Xie W, Potluri P, Lott MT, Zhang S, Saeed M, Murdock DG, Weiss SR, Douam F, Wallace DC.   +21 more
europepmc   +1 more source

Review of CFD modelling techniques for single‐phase and multiphase flow in static mixers

The Canadian Journal of Chemical Engineering, EarlyView.
This review synthesizes computational fluid dynamics (CFD) approaches for static mixers, linking hydrodynamics to pressure drop, particle/droplet distributions, mixing metrics, and heat‐transfer performance to guide modelling choices and design decisions. Abstract Static mixers enable compact and low‐energy intensification.
Jussan Jaeger, Sálvio Lima de Carvalho Neto, Silvio Edegar Weschenfelder, Glaucia Rodrigues Vieira de Almeida da Fonseca, Maria de Fátima Rodrigues da Cunha, Selene Maria Arruda Guelli Ulson de Souza, Evandro Balestrin, Adriano da Silva   +7 more
wiley   +1 more source

SARS-CoV-2 ORF8: an accessory protein at the interface of immune evasion and inflammation. [PDF]

Front Immunol
Schäfer C, Blamey C, Balbiano R, Mena J, Acuña-Castillo C, Sandino AM.   +5 more
europepmc   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

Structure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants. [PDF]

J Med Chem
Raasch N, Weißenborn L, Richel E, Schäfer S, Denysenko O, Bartelsen N, Sticht H, Überla K, Eichler J.   +8 more
europepmc   +1 more source

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

Clinical Pharmacology &Therapeutics, EarlyView.
New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Karen Rowland Yeo, Piet H. van der Graaf
wiley   +1 more source

Discovery of Novel SARS-CoV-2 Fusion Inhibitors-Posaconazole-Polyarginine Conjugates. [PDF]

Viruses
Jin Y, Qu L, Gao X, Qi X, Zhao D, Ga L, Zhao Y, Liang G, Xiao Y, Ma Y.   +9 more
europepmc   +1 more source

Velociraptor Machine Learning Quantifies Similarity to Known Cell Types and Matches Cells Across Flow and Imaging Cytometry Platforms

Cytometry Part A, EarlyView.
ABSTRACT Suspension flow cytometry enables high‐throughput cellular profiling at the single cell level, but these data lack positional information. Conversely, tissue‐based imaging cytometry techniques reveal a cell's location within the tissue architecture and can provide insight into cell biology.
Claire E. Cross, Asa A. Brockman, Rebecca A. Ihrie, Jonathan M. Irish   +3 more
wiley   +1 more source

A distinct effector B cell population drives autoantibody production in SARS-CoV-2 infection. [PDF]

Immunity
Yuan D, Li S, Zhang R, Ng RH, Su Y, Lan L, Shome M, Smith B, Troisch P, Xie J, Choi J, Edmark R, Chen D, Rowen L, Nguyen A, Liu R, Gutierrez V, Brennan C, McKasson M, Murray K, Wallick JA, Algren HA, Duven A, Piening B, Thomas W, Kueh HY, Magis AT, Hadlock J, Snyder M, Goldman JD, Heath JR.   +30 more
europepmc   +1 more source